G Michelle Ducasa1,2, Alla Mitrofanova1,2,3, Alessia Fornoni4,5. 1. Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine, 1580 NW 10th Avenue, Miami, FL, USA. 2. Peggy and Harold Katz Family Drug Discovery Center, University of Miami, Miller School of Medicine, Miami, FL, USA. 3. Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA. 4. Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine, 1580 NW 10th Avenue, Miami, FL, USA. afornoni@miami.edu. 5. Peggy and Harold Katz Family Drug Discovery Center, University of Miami, Miller School of Medicine, Miami, FL, USA. afornoni@miami.edu.
Abstract
PURPOSE OF REVIEW: The goal of this review is to review the role that renal parenchymal lipid accumulation plays in contributing to diabetic kidney disease (DKD), specifically contributing to the mitochondrial dysfunction observed in glomerular renal cells in the context of DKD development and progression. RECENT FINDINGS: Mitochondrial dysfunction has been observed in experimental and clinical DKD. Recently, Ayanga et al. demonstrate that podocyte-specific deletion of a protein involved in mitochondrial dynamics protects from DKD progression. Furthermore, our group has recently shown that ATP-binding cassette A1 (a protein involved in cholesterol and phospholipid efflux) is significantly reduced in clinical and experimental DKD and that genetic or pharmacological induction of ABCA1 is sufficient to protect from DKD. ABCA1 deficiency in podocytes leads to mitochondrial dysfunction observed with alterations of mitochondrial lipids, in particular, cardiolipin (a mitochondrial-specific phospholipid). However, through pharmacological reduction of cardiolipin peroxidation DKD progression is reverted. Lipid metabolism is significantly altered in the diabetic kidney and renders cellular components, such as the podocyte, susceptible to injury leading to worsened DKD progression. Dysfunction of the lipid metabolism pathway can also lead to mitochondrial dysfunction and mitochondrial lipid alteration. Future research aimed at targeting mitochondrial lipids content and function could prove to be beneficial for the treatment of DKD.
PURPOSE OF REVIEW: The goal of this review is to review the role that renal parenchymal lipid accumulation plays in contributing to diabetic kidney disease (DKD), specifically contributing to the mitochondrial dysfunction observed in glomerular renal cells in the context of DKD development and progression. RECENT FINDINGS: Mitochondrial dysfunction has been observed in experimental and clinical DKD. Recently, Ayanga et al. demonstrate that podocyte-specific deletion of a protein involved in mitochondrial dynamics protects from DKD progression. Furthermore, our group has recently shown that ATP-binding cassette A1 (a protein involved in cholesterol and phospholipid efflux) is significantly reduced in clinical and experimental DKD and that genetic or pharmacological induction of ABCA1 is sufficient to protect from DKD. ABCA1 deficiency in podocytes leads to mitochondrial dysfunction observed with alterations of mitochondrial lipids, in particular, cardiolipin (a mitochondrial-specific phospholipid). However, through pharmacological reduction of cardiolipin peroxidation DKD progression is reverted. Lipid metabolism is significantly altered in the diabetic kidney and renders cellular components, such as the podocyte, susceptible to injury leading to worsened DKD progression. Dysfunction of the lipid metabolism pathway can also lead to mitochondrial dysfunction and mitochondrial lipid alteration. Future research aimed at targeting mitochondrial lipids content and function could prove to be beneficial for the treatment of DKD.
Authors: Amandeep Bajwa; Liping Huang; Elvira Kurmaeva; Hong Ye; Krishna R Dondeti; Piotr Chroscicki; Leah S Foley; Z Ayoade Balogun; Kyle J Alexander; Hojung Park; Kevin R Lynch; Diane L Rosin; Mark D Okusa Journal: J Am Soc Nephrol Date: 2016-10-31 Impact factor: 10.121
Authors: Tae-Hyun Yoo; Christopher E Pedigo; Johanna Guzman; Mayrin Correa-Medina; Changli Wei; Rodrigo Villarreal; Alla Mitrofanova; Farah Leclercq; Christian Faul; Jing Li; Matthias Kretzler; Robert G Nelson; Markku Lehto; Carol Forsblom; Per-Henrik Groop; Jochen Reiser; George William Burke; Alessia Fornoni; Sandra Merscher Journal: J Am Soc Nephrol Date: 2014-06-12 Impact factor: 10.121
Authors: Johannes Bischof; Manuel Salzmann; Maria Karolin Streubel; Jiri Hasek; Florian Geltinger; Jutta Duschl; Nikolaus Bresgen; Peter Briza; Danusa Haskova; Renata Lejskova; Mentor Sopjani; Klaus Richter; Mark Rinnerthaler Journal: Cell Death Discov Date: 2017-03-20
Authors: Regina F Sultanova; Ryan Schibalski; Irina A Yankelevich; Krisztian Stadler; Daria V Ilatovskaya Journal: Am J Physiol Renal Physiol Date: 2020-11-02